Sign in
Taking people in United StatesPhase 2

Cannabidiol to reduce opioid use after knee replacement surgery

Tests cannabidiol for opioid pain medicine needs in people having knee replacement.

Key facts

Who runs it
Chad Brummett
Where
Ann Arbor and Detroit, United StatesSee the 2 sites
Trial code
Registry title
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty
Status
Recruiting
Phase
Phase 2
People taking part
380 people, planned
Started
13 Mar 2024
Expected to end
Jan 2029
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Epidiolex oral solution
  • Placebo
Record updated
15 April 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with knee osteoarthritis who are scheduled for a first total knee replacement. It tests whether CBD (Epidiolex) lowers the need for opioid pain medicine after surgery.

Age
18 Years to 80 Years
Sex
All
Disease stage
Osteoarthritis is the main diagnosis in the knee being operated on. Surgery must be a first (primary) total knee replacement, not a repeat surgery and not both knees.
Earlier treatment
No cannabis products in the 7 days before starting the study drug. People who used cannabis 8-30 days before need a clean drug test or a confirmed break. People taking a high daily opioid dose before surgery cannot join. Opioids taken on a prescription and reported are allowed.

Main reasons for not taking part

  • Repeat knee replacement or both knees replaced at once
  • Major brain or nerve disorders, such as dementia, Parkinson's disease, epilepsy or head injury
  • Liver cirrhosis, active hepatitis, or high liver enzymes or bilirubin on blood tests
  • Current use of valproate, clobazam or warfarin
  • Pregnant or breastfeeding women

The registry criteria, word for word

Show all 34 criteriaShow less

Who can take part

  • Willing and able to read, understand, and sign the informed consent (English)
  • Willingness to participate in all study measures and restrictions, including patient-reported outcomes and longitudinal follow-up
  • Scheduled for surgery: primary total knee arthroplasty
  • Primary diagnosis of osteoarthritis of the surgical knee
  • Individuals of reproductive potential must agree to use acceptable birth control (defined in manual of operating procedures). This includes currently practicing an effective form of two types of birth control for women of childbearing potential, which are defined as those, alone or in combination, that result in a low failure rate (i.e., less than 1% per year) when used consistently and correctly from the screening visit until 28 days after the last study drug administration
  • Participants must also agree not to donate sperm or eggs during study drug administration
  • Ability to take and to swallow the study medication and be willing to adhere to the treatment regimen
  • Agreement to adhere to Lifestyle Considerations (see protocol) throughout study duration

Who cannot take part

  • Individuals receiving or actively applying for worker's compensation or disability and other aspects associated with potential secondary gain (postoperative disability for recovery is permitted)
  • Illicit drug use (other than cannabis). Unreported opioid use would be exclusionary but reported prescribed opioid use is allowed (e.g. patient denies opioid use but is found to be positive on the urine drug screen)
  • Self-reported use of cannabis products within the 7 days prior to starting study drug
  • Self-reported use of cannabis products within the 8-30 days prior to starting study drug AND either a failed drug screen or inability to confirm successful washout (Note - may be rescreened with appropriate wash-out period)
  • Self-reported severe side effects to opioids precluding the use of opioids for post-surgical pain and/or clear plan not to use any opioids after surgery and confirmed by the investigator during screening
  • Severe physical impairment or clinically significant illness (e.g., blindness, paraplegia)
  • Co-morbid medical conditions that may significantly impair physical functional status (e.g., current non-skin malignancies, solid organ transplant in the past year)
  • Individuals with major neurological disorders, such as dementia, Parkinson's disease, cognitive impairment, epilepsy, history of traumatic brain injury/head injury, and seizures
  • Medical or psychiatric conditions that in the judgment of study personnel would preclude participation in this study (e.g., psychosis, suicidal ideation; note that stable anxiety and depression are not exclusions)
  • Self-reported uncontrolled diabetes
  • Self-reported active hepatitis (any etiology, including infectious, autoimmune, or alcohol-related)
  • Resting heart rate at screening less than 50 beats per minute (bpm) or greater than 100 bpm; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements
  • Severe cardiovascular disease (e.g., current unstable angina, current congestive heart failure, or current severe valvular abnormalities) that is self-reported by patient or in medical record
  • Self-reported allergies to sesame oil, strawberries, opioids, or cannabis/cannabinoids and confirmed by the investigator during screening
  • Any impairment, activity, behavior, or situation that in the judgment of the study team would prevent satisfactory completion of the study protocol
  • Individuals with significant illness (e.g., cancer) and/or clinically significant labs (e.g. labs measured by complete blood count (CBC) and basic chemistry with values meaningfully outside of the normal range [abnormal levels to be reviewed by the Principal Investigator or prescribing provider])
  • Elevated liver enzymes and bilirubin (measured by blood test at screening)
  • Serum total bilirubin ≥ 2.5 milligrams (mg) per deciliter (dL) (mg/dL); or,; Alanine transaminase (ALT) or Alanine transaminase (AST) ≥ 3x upper limit normal (ULN); or,; Alkaline phosphatase ≥ 2x ULN
  • Revision or bilateral total knee arthroplasty
  • High daily preoperative opioid dose
  • Pregnant or nursing women (total joint arthroplasty is typically not indicated in this group of patients)
  • Self-reported liver cirrhosis
  • Blood pressure at screening above 180 millimeters of mercury (mmHg) systolic and/or 120 mmHg diastolic; if value exceeds the set point, potential participants will have repeat assessment within 5 minutes for up to two additional measurements
  • Current valproate, clobazam, or warfarin use per self-report or medical records
  • Current use of strong inducers of cytochrome p450 (CYP) enzymes CYP3A4 and CYP2C19, or CYP2C19 substrates with a narrow therapeutic index
  • Participation in other clinical trials over the course of this study (note: outside of active period is permissible as determined by the investigator during screening)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • University of MichiganAnn Arbor, United StatesContact: Kendall DuboisTaking people
  • Henry Ford Health SystemDetroit, United StatesContact: Katherine NowakNot yet recruiting

About the trial

What the trial wants to find out

The goal of this study is to better understand how daily treatment with cannabidiol (CBD) affects the need for opioid pain medication, as well as pain, inflammation and other related symptoms, after knee replacement surgery. The information collected in this study is necessary to help understand whether CBD may be a useful medication before and/or after surgery.

Read full original descriptionShow less

The study hypothesis is that CBD exerts opioid-sparing effects through anti-inflammatory, analgesic, and anxiolytic mechanisms.

The 4 groups in the trial

  • Pre - and post-operative CBDTreatment being tested

    Participants will take 300 milligrams (mg)/day on days 1-36 (150mg twice a day \[b.i.d.\])

    Treatment: Epidiolex oral solution

  • Pre-operative placebo plus post-operative CBDTreatment being tested

    Participants will take placebo prior to surgery days 1-7, then days 8-36 participants will take CBD 300 milligrams (150mg twice a day \[b.i.d.\])

    Treatment: Epidiolex oral solution and Placebo

  • Pre-operative CBD plus post-operative placeboTreatment being tested

    Participants will take CBD 300 milligrams (mg) /day prior to surgery on days 1-7 (150mg twice a day \[b.i.d.\]), then days 8-36 will take placebo twice a day \[b.i.d.\]

    Treatment: Epidiolex oral solution and Placebo

  • Pre- and post-operative placeboPlacebo, for comparison

    Participants will take placebo on days 1-36 twice a day \[b.i.d.\]

    Treatment: Placebo

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Cannabidiol for Postoperative Opioid Reduction in Primary Total Knee Arthroplasty - a Randomized, Two by Two Factorial, Double-blind, Placebo-controlled Clinical Trial
Plain-language title
Cannabidiol to reduce opioid use after knee replacement surgeryGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT06234631, who can take part
Record updated
15 April 2026